Bosutinib (BosulifÒ, Pfizer Europe), a second generation TKI, was created for patients unresponsive or intolerant to imatinib, nilotinib or dasatinib.
Bosutinib is approved for:
- Patients with newly‑diagnosed CML
- Patients previously treated with one or more TKIs
- Patients in whom imatinib, nilotinib and dasatinib are not appropriate
